Cells. 2019 Mar 19;8(3). pii: E258. doi: 10.3390/cells8030258.

Effect of MSCs and MSC-Derived Extracellular Vesicles on Human Blood Coagulation.

Silachev DN^1,2, Goryunov KV³, Shpilyuk MA⁴, Beznoschenko OS⁵, Morozova NY⁶, Kraevaya EE⁷, Popkov VA^8,9, Pevzner IB^10,11, Zorova LD^12,13, Evtushenko EA¹⁴, Starodubtseva NL^15,16, Kononikhin AS^17,18, Bugrova AE^19,20, Evtushenko EG²¹, Plotnikov EY^22,23, Zorov DB^24,25, Sukhikh GT^26,27.

Abstract

Mesenchymal stem cells (MSCs) have emerged as a potent therapeutic tool for the treatment of a number of pathologies, including immune pathologies. However, unwelcome effects of MSCs on blood coagulation have been reported, motivating us to explore the thrombotic properties of human MSCs from the umbilical cord. We revealed strong procoagulant effects of MSCs on human blood and platelet-free plasma using rotational thromboelastometry and thrombodynamic tests. A similar potentiation of clotting was demonstrated for MSC-derived extracellular vesicles (EVs). To offer approaches to avoid unwanted effects, we studied the impact of a heparin supplement on MSC procoagulative properties. However, MSCs still retained procoagulant activity toward blood from children receiving a therapeutic dose of unfractionated heparin. An analysis of the mechanisms responsible for the procoagulant effect of MSCs/EVs revealed the presence of tissue factor and other proteins involved in coagulation-associated pathways. Also, we found that some MSCs and EVs were positive for annexin V, which implies the presence of phosphatidylserine on their surfaces, which can potentiate clot formation. Thus, we revealed procoagulant activity of MSCs/EVs associated with the presence of phosphatidylserine and tissue factor, which requires further analysis to avoid adverse effects of MSC therapy in patients with a risk of thrombosis.